Try our Advanced Search for more refined results

IN RE ASACOL ANTITRUST LITIGATION

  1. January 05, 2017

    Warner Chilcott Denied Sales Docs In Asacol Antitrust Suit

    Warner Chilcott lost a bid Wednesday to force wholesalers and others to produce sales data in their pay-for-delay antitrust litigation over ulcerative colitis drugs despite claiming it needed the discovery to avoid duplicative damages.

  2. December 21, 2016

    Warner Chilcott Urges Judge To Nix Asacol Antitrust Claims

    Warner Chilcott asked a federal judge in Boston Wednesday to nix allegations from supermarket pharmacies and other direct purchasers that it used anticompetitive lawsuits and a bogus new formulation to keep prices of ulcerative colitis drug Asacol artificially high.

  3. December 07, 2016

    Colitis Drug Buyers Fight Doc Requests In Antitrust Row

    Direct purchasers in a consolidated proposed antitrust class action over an ulcerative colitis treatment asked a Massachusetts federal judge to not force them to produce documentation on nine other related drugs, arguing Tuesday that such requests are unnecessary and burdensome.

  4. October 12, 2016

    Warner Chilcott Wants Claims Cut In Generic-Blocking Suit

    Warner Chilcott Ltd. urged a Massachusetts federal court to toss claims made by direct purchasers in a consolidated proposed antitrust class action over a drug for ulcerative colitis, arguing that their reverse payment claims do not hold up and that they lack standing to pursue the claims.

  5. July 21, 2016

    Warner Chilcott, Zydus Face Leaner Product-Hop Suit

    A Massachusetts federal judge trimmed some state-based claims against Warner Chilcott Ltd. and reverse-payment claims against it and generics maker Zydus Pharmaceuticals USA Inc. in a putative antitrust class action over a drug for ulcerative colitis, but left product-hopping claims intact.

  6. February 19, 2016

    Warner Chilcott Aims To Nix Suits Alleging Generic Blocking

    Warner Chilcott Ltd. has asked a federal judge to toss proposed class actions that claim the drugmaker pulled an illegal “hard switch” by taking ulcerative colitis drug Asacol off-market to prevent generic competition, arguing there is nothing illegal about making changes required by the federal government.

  7. June 23, 2015

    Allergan Pulled 'Hard Switch' To Block Generics, Unions Say

    Union health groups lodged two proposed class actions in Massachusetts federal court Monday alleging Warner Chilcott Ltd., now of Allergan PLC, pulled an illegal "hard switch" by taking ulcerative colitis drug Asacol off-market to prevent generic competition.